Therefore, discovering an inhibitor, such as KRB-456, which binds KRAS G12D and KRAS G12V, will have a broader impact on human cancers, particularly in PDAC, colorectal cancer, and other cancers where the incidence of KRAS G12D and KRAS G12V mutations is significant. This evidence concerns the gene KRAS and colorectal cancer.